CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
Toronto, Ontario, Canada and 13 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Toronto, Ontario, Canada and 89 other locations
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...
Phase 1, Phase 2
Toronto, Ontario, Canada and 31 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
Toronto, Ontario, Canada and 55 other locations
targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non- ...
Phase 1
Toronto, Ontario, Canada and 19 other locations
with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...
Phase 1, Phase 2
Hamilton, Ontario, Canada and 28 other locations
participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...
Phase 3
Toronto, Ontario, Canada and 62 other locations
monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...
Phase 2
Toronto, Ontario, Canada and 44 other locations
or Pola-R-CHP in participants with untreated diffuse large B-cell lymphoma (DLBCL). Evaluating the safety, preliminary activity, pharmacokin...
Phase 1
Toronto, Ontario, Canada and 23 other locations
lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...
Phase 1, Phase 2
Toronto, Canada and 29 other locations
Clinical trials
Research sites
Resources
Legal